COVID-19 and the newly rediscovered multidisciplinarity

Immunotherapy. 2020 Oct;12(15):1101-1103. doi: 10.2217/imt-2020-0205. Epub 2020 Sep 21.

Author

Melissa Bersanelli^{1

2}

Affiliations

¹ Department of General and Specialistic Medicine, University Hospital of Parma, Medical Oncology Unit, Parma, Italy.
² Department of Medicine & Surgery, University of Parma, Parma, Italy.

No abstract available

Keywords: COVID-19; SARS-CoV-2; anti-PD-1/PD-L1; immunosuppressed; immunotherapy; janus kinase inhibitors; pandemic; tocilizumab; virus.

Publication types

Introductory Journal Article

MeSH terms

Anticoagulants / therapeutic use
Betacoronavirus
COVID-19
Coronavirus Infections / epidemiology
Coronavirus Infections / immunology
Coronavirus Infections / prevention & control
Coronavirus Infections / therapy*
Humans
Immunocompromised Host
Immunologic Factors / therapeutic use
Immunotherapy
Interdisciplinary Research*
Pandemics / prevention & control
Pneumonia, Viral / epidemiology
Pneumonia, Viral / immunology
Pneumonia, Viral / prevention & control
Pneumonia, Viral / therapy*
SARS-CoV-2

Substances

Anticoagulants
Immunologic Factors